MX2023004085A - Metodos para el tratamiento del cáncer. - Google Patents

Metodos para el tratamiento del cáncer.

Info

Publication number
MX2023004085A
MX2023004085A MX2023004085A MX2023004085A MX2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A
Authority
MX
Mexico
Prior art keywords
egfr
her2
cancer
treatment
disorder
Prior art date
Application number
MX2023004085A
Other languages
English (en)
Spanish (es)
Inventor
Angel Guzman-Perez
Ryan D White
Benjamin C Milgram
Jean Jr David St
Original Assignee
Scorpion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics Inc filed Critical Scorpion Therapeutics Inc
Publication of MX2023004085A publication Critical patent/MX2023004085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023004085A 2020-10-09 2021-10-08 Metodos para el tratamiento del cáncer. MX2023004085A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089965P 2020-10-09 2020-10-09
US202163151468P 2021-02-19 2021-02-19
PCT/US2021/054191 WO2022076831A2 (en) 2020-10-09 2021-10-08 Methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2023004085A true MX2023004085A (es) 2023-06-29

Family

ID=78516928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004085A MX2023004085A (es) 2020-10-09 2021-10-08 Metodos para el tratamiento del cáncer.

Country Status (13)

Country Link
US (1) US20240101576A1 (enExample)
EP (1) EP4225445A2 (enExample)
JP (1) JP2023548657A (enExample)
KR (1) KR20230107419A (enExample)
AU (1) AU2021358596A1 (enExample)
BR (1) BR112023006531A2 (enExample)
CA (1) CA3198202A1 (enExample)
CL (2) CL2023001012A1 (enExample)
IL (1) IL301929A (enExample)
MX (1) MX2023004085A (enExample)
PH (1) PH12023500010A1 (enExample)
TW (1) TW202227063A (enExample)
WO (1) WO2022076831A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
US20250282795A1 (en) * 2022-04-20 2025-09-11 Celyn Therapeutics, Inc. EGFR Inhibitors in cancer treatment
EP4637754A2 (en) * 2022-12-23 2025-10-29 Tay Therapeutics Limited Selective bet inhibitors and uses thereof
CN115819418B (zh) * 2023-02-14 2023-04-28 山东绿叶制药有限公司 Plk1激酶抑制剂及其制备方法和应用
CN121712773A (zh) 2023-06-08 2026-03-20 安塔列斯疗法股份有限公司 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗
WO2024254298A1 (en) * 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
CN119528906A (zh) * 2023-08-30 2025-02-28 中国科学院上海药物研究所 氮杂螺环类化合物及其制备方法、药物组合物和应用
EP4534085A1 (en) * 2023-10-03 2025-04-09 Scorpion Therapeutics, Inc. Compounds for use in methods of treating cancer
WO2025251058A1 (en) * 2024-05-31 2025-12-04 Celyn Therapeutics, Inc. Egfr inhibitors in cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906194B2 (en) 2003-10-08 2005-06-14 Massachusetts Instititue Of Technology Fluorescence assay for kinase activity
US7964729B2 (en) 2006-08-28 2011-06-21 Massachusetts Institute Of Technology Sox-based kinase sensor
US8546413B2 (en) * 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
JP5825932B2 (ja) 2011-08-26 2015-12-02 キヤノン株式会社 撮像装置及びその制御方法、プログラム、及び記録媒体
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
ES2620316T3 (es) 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
WO2014147204A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
HK1218750A1 (zh) 2013-03-21 2017-03-10 Bayer Pharma Aktiengesellschaft 3-杂芳基取代的吲唑
HK1223097A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑
HK1222846A1 (zh) 2013-06-21 2017-07-14 Bayer Pharma Aktiengesellschaft 取代的苄基吡唑
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
EP3157914B1 (en) 2014-06-17 2018-09-26 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
TN2017000329A1 (en) * 2015-01-28 2019-01-16 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CN107922389A (zh) 2015-06-17 2018-04-17 拜耳制药股份公司 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
US10308629B2 (en) 2015-08-05 2019-06-04 Bayer Pharma Aktiengesellschaft 1H-pyrrol-3-amines
JP6141568B1 (ja) 2015-09-01 2017-06-07 大鵬薬品工業株式会社 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
EP3700904B1 (en) * 2017-10-24 2023-07-19 Bayer AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3755323A4 (en) 2018-02-23 2021-11-24 The Regents Of The University Of Michigan EGFR DIMER DISRUPTORS AND THEIR USES
CN112236417A (zh) 2018-06-14 2021-01-15 达纳-法伯癌症研究所股份有限公司 作为her2抑制剂的氰基喹啉酰胺化合物及使用方法
WO2019246541A1 (en) 2018-06-21 2019-12-26 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
EP3921317B1 (en) * 2019-02-07 2023-08-02 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors

Also Published As

Publication number Publication date
BR112023006531A2 (pt) 2023-10-03
IL301929A (en) 2023-06-01
CA3198202A1 (en) 2022-04-14
WO2022076831A2 (en) 2022-04-14
EP4225445A2 (en) 2023-08-16
CL2023001012A1 (es) 2023-12-22
US20240101576A1 (en) 2024-03-28
TW202227063A (zh) 2022-07-16
KR20230107419A (ko) 2023-07-14
PH12023500010A1 (en) 2024-03-11
CL2025004052A1 (es) 2026-03-20
JP2023548657A (ja) 2023-11-20
AU2021358596A9 (en) 2024-10-24
WO2022076831A3 (en) 2022-07-07
AU2021358596A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
PH12023500010A1 (en) Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer
MX2023003362A (es) Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2020150417A3 (en) Compounds and compositions for treating conditions associated with sting activity
ES2436225T3 (es) Inhibidores TRPA1 para tratamiento del dolor
WO2022072645A3 (en) Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer
PH12023550130A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
PH12021500049A1 (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
JOP20220332A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
CN107613983B (zh) 抗肿瘤剂的副作用减轻剂
WO2022133046A3 (en) Compounds and compositions for treating conditions associated with sting activity
CR20230185A (es) Compuestos y su uso en el tratamiento del cáncer
MY145634A (en) Pyrrolotriazine compounds as kinase inhibitors
EP3313410A1 (en) Compositions and methods for inhibiting arginase activity
MX2023009857A (es) Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos.
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
MX2025004532A (es) Método para tratar el cáncer
WO2005065266A8 (en) Di-substituted pyrrolotriazine compounds
MX2021002109A (es) Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer.
WO2022133098A3 (en) Compounds and compositions for treating conditions associated with sting activity
RU2013148817A (ru) Комбинации соединений-ингибиторов акт и мек и способы их применения
WO2023107723A3 (en) Cyclic compounds and their use for the treatment of neurological disorders
EA200870454A1 (ru) Способ ингибирования c-kit киназы
MX2024012937A (es) Inhibidores del receptor del factor de crecimiento epidérmico en el tratamiento de cáncer
JOP20240022A1 (ar) مركبات وتركيبات لعلاج حالات مرتبطة بنشاط sting